Titlebook: Neoplastic Diseases of the Blood; Peter H. Wiernik,Janice P. Dutcher,Morie A. Gertz Textbook 2018Latest edition Springer International Pub

大小

書(shū)目名稱(chēng)Neoplastic Diseases of the Blood影響因子(影響力)




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood被引頻次




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood被引頻次學(xué)科排名




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood年度引用




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood年度引用學(xué)科排名




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood讀者反饋




書(shū)目名稱(chēng)Neoplastic Diseases of the Blood讀者反饋學(xué)科排名

Decimate

Epidemiology and Etiology of Chronic Myeloid Leukemial sparse. CML incidence rates vary from 0.6 to 2.8 cases per 100,000 inhabitants with an obvious increase in age, and men are more often affected than women. Geographic and/or ethnic variations and diagnostic accurateness might contribute to the seen variability. CML can be induced by acute high-dos

Cirrhosis

Pathology of the Chronic Myeloid Leukemias, leading to a purely myeloid phenotype, or a lymphoid-myeloid stem cell, potentially giving rise to a mixed phenotype leukemia. These leukemias are categorized partly on the basis of clinicopathological features and partly on the basis of the underlying cytogenetic/molecular genetic abnormalities.

exophthalmos

interrogate

品嘗你的人

gene-therapy

Morphology and Immunophenotype of Chronic Lymphocytic Leukemia involvement. Lymphadenopathy and proliferation in extramedullary tissues are often seen. The key to the precise diagnosis of CLL begins with assessment of the cytomorphology of the neoplastic cells, often from peripheral blood, but also the architectural patterns of involvement from tissue sections

皺痕

The Genomic and Epigenomic Landscape of Chronic Lymphocytic Leukemiadel to understand the processes of cancer progression and evolution. Genome-wide genomic and epigenetic approaches have delivered an unparalleled view of the architecture of the CLL (epi)genome, so that we now possess an extensive catalogue of the copy number, mutational and epigenetic landscape of

Deject

Treatment of Chronic Lymphocytic Leukemia and Related Disordersus, and other disease-specific characteristics. According to SEER data, in 2016, there will be 18,960 new cases of CLL diagnosed and more than 100,000 people with CLL living in the USA (.). Fludarabine, cyclophosphamide, and rituximab is an effective regimen in CLL, producing long-term survivors. Ho

flaunt

Hairy Cell Leukemia(hairy cells) infiltrating the bone marrow and spleen, leading to pancytopenia, bone marrow fibrosis, and splenic enlargement. Hairy cells have a unique immunophenotypic profile—CD11c+, CD20+, CD25+, and CD103+—that confirms its diagnosis. The course of HCL is usually chronic, but can often be progr